Pathologic features of 64 patients with primary HHV8-negative EBL
| Variable . | Immunohistochemistry . | Flow cytometry . |
|---|---|---|
| CD3 | 1/35 (3) | 2/48 (4) |
| CD5 | 2/20 (10) | 14/51 (27) |
| CD10 | 5/41 (12) | 11/51 (22) |
| CD19 | — | 46/52 (88) |
| CD20 | 49/53 (92) | 50/53 (94) |
| CD30 | 1/32 (3) | 4/35 (11) |
| CD38 | 8/32 (25) | 6/11 (55) |
| CD79a | 26/28 (93) | — |
| CD138 | 4/34 (12) | 0/6 (0) |
| BCL2 | 8/9 (89) | — |
| BCL6 | 14/36 (39) | — |
| MUM1 | 27/38 (71) | — |
| κ+/λ- | — | 23/50 (46) |
| κ-/λ+ | — | 12/50 (24) |
| κ-/λ- | — | 12/50 (24) |
| EBER ISH | 6/45 (13) | — |
| Ki-67 proliferation index (N = 35), % | ||
| Median | 73.5 | — |
| Range | 3-93 | — |
| Cell-of-origin classification according to the Hans algorithm | ||
| Germinal center phenotype | 8/38 (21) | — |
| Non–germinal center phenotype | 30/38 (79) | — |
| BCL2/IGH (FISH) | 1/6 (17) | — |
| BCL6/IGH (FISH) | 2/9 (22) | — |
| MYC rearrangement (FISH) | 7/36 (19) | — |
| Variable . | Immunohistochemistry . | Flow cytometry . |
|---|---|---|
| CD3 | 1/35 (3) | 2/48 (4) |
| CD5 | 2/20 (10) | 14/51 (27) |
| CD10 | 5/41 (12) | 11/51 (22) |
| CD19 | — | 46/52 (88) |
| CD20 | 49/53 (92) | 50/53 (94) |
| CD30 | 1/32 (3) | 4/35 (11) |
| CD38 | 8/32 (25) | 6/11 (55) |
| CD79a | 26/28 (93) | — |
| CD138 | 4/34 (12) | 0/6 (0) |
| BCL2 | 8/9 (89) | — |
| BCL6 | 14/36 (39) | — |
| MUM1 | 27/38 (71) | — |
| κ+/λ- | — | 23/50 (46) |
| κ-/λ+ | — | 12/50 (24) |
| κ-/λ- | — | 12/50 (24) |
| EBER ISH | 6/45 (13) | — |
| Ki-67 proliferation index (N = 35), % | ||
| Median | 73.5 | — |
| Range | 3-93 | — |
| Cell-of-origin classification according to the Hans algorithm | ||
| Germinal center phenotype | 8/38 (21) | — |
| Non–germinal center phenotype | 30/38 (79) | — |
| BCL2/IGH (FISH) | 1/6 (17) | — |
| BCL6/IGH (FISH) | 2/9 (22) | — |
| MYC rearrangement (FISH) | 7/36 (19) | — |
Unless otherwise indicated, data are n/N (%).
EBER ISH, Epstein-Barr virus–encoded small RNA in situ hybridization; FISH, fluorescent in situ hybridization.